CANNAPHARMARX, INC.
Data quality: 100%
CPMD
OTC
Manufacturing
Chemicals
$0.00
$0.00
(0.00%)
Mkt Cap: 2.71 M
Price
$0.00
Mkt Cap
2.71 M
Day Range
$0.00 — $0.00
52-Week Range
$0.00 — $0.01
Volume
2,100
Open $0.00
50D / 200D Avg
$0.00
2.44% below
50D / 200D Avg
$0.00
0.00% above
Quick Summary
Key Takeaways
Negative free cash flow of -794,621.0
Capital efficient — spends only 0.41% of revenue on capex
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)66.09%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
N/A
ROICN/A
Net Margin-817.19%
Op. Margin-245.77%
Safety
Debt / Equity
N/A
Current Ratio0.05
Interest Coverage-1.71
Valuation
PE (TTM)
-0.24
Above sector avg (-1.47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -0.2 | -1.5 |
| P/B | — | 1.6 |
| ROE % | — | -53.5 |
| Net Margin % | -817.2 | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 66.09% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 1.36 M | Net Income (TTM) | -11.13 M |
| ROE | N/A | ROA | -96.42% |
| Gross Margin | -153.06% | Operating Margin | -245.77% |
| Net Margin | -817.19% | Free Cash Flow (TTM) | -794,621.0 |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0.05 |
| Interest Coverage | -1.71 | Asset Turnover | 0.12 |
| Working Capital | -27.01 M | Tangible Book Value | -22.52 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.24 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 1.99 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -29.28% | ||
| Market Cap | 2.71 M | Enterprise Value | 2.71 M |
| Per Share | |||
| EPS (Diluted TTM) | -0.02 | Revenue / Share | 0.00 |
| FCF / Share | 0.00 | OCF / Share | 0.00 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0.41% | FCF Conversion | 7.14% |
| SBC-Adj. FCF | -794,621 | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 1.36 M | 820,137.0 | 0.0 | 0.0 | 0.0 |
| Net Income | -11.13 M | -9.91 M | -8.53 M | -8.83 M | -19.89 M |
| EPS (Diluted) | -0.02 | -0.02 | 0.04 | — | — |
| Gross Profit | -2.08 M | -2.93 M | — | — | — |
| Operating Income | -3.35 M | -3.61 M | -5.21 M | -2.99 M | -14.49 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | — | — | — |
| SG&A Expenses | — | 116,640.0 | — | — | — |
| D&A | — | 0.0 | 294,934.0 | 2,708.0 | 128,505.0 |
| Interest Expense | 1.96 M | 2.26 M | 2.29 M | 1.51 M | 2.29 M |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 7.02 M | 10.84 M | 5.41 M | 114,330.0 | 8.75 M |
| Total Liabilities | 37.17 M | 30.65 M | 22.76 M | 13.04 M | 17.55 M |
| Shareholders' Equity | -30.15 M | -19.81 M | -17.34 M | -12.93 M | -8.80 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 1,804.0 | 2,156.0 | 2,317.0 | 27,767.0 | 334,969.0 |
| Current Assets | 1.31 M | 1.02 M | 100,014.0 | 29,538.0 | 467,551.0 |
| Current Liabilities | 31.59 M | 25.75 M | 17.17 M | 13.04 M | 17.55 M |
{"event":"ticker_viewed","properties":{"ticker":"CPMD","listing_kind":"stock","pathname":"/stocks/cpmd","exchange":"OTC","country":"US"}}